Fella Health vs MyFastRx
Two GLP-1 desks, one scoreboard. We put Fella Health and MyFastRx head-to-head on the published Brief Score — the same six factors, scored the same way.
Fella Health
The verdict
Fella Health takes this head-to-head.
Fella Health scores 81 to 79 on our six-factor Brief Score — A men's-health-focused program with an honest published state list — but a steep $399 tirzepatide line and no accreditation badge.
That doesn't make MyFastRx a bad call — it's best for readers who want cash-pay patients comfortable with 12-month upfront billing for the lowest compounded-glp-1 monthly rate. Weigh the six factors below against your own priorities before you decide.
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.
Factor by factor
Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.
Price, coverage & the tracker
| Fella Health | MyFastRx | |
|---|---|---|
| Brief Score | 81/100 (B−) | 79/100 (C) |
| Semaglutide | $165/mo | $169/mo |
| Tirzepatide | $399/mo | $249/mo |
| Coverage | 20 states | All 50 states |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Injection only |
| On the tracker | Stableprice stable | Newnew to the tracker, no prior reading |
Fella Health: $165 sema but $399 tirz — one of the higher tirz lines; ~20 states, no accreditation.
MyFastRx: New to the tracker on 1 August 2026. The published line reads $169/mo at our first reading; there is no earlier reading of ours to compare it against yet.
● Not sold on either?
CoreAge Rx tops the whole ranking at 94/100.
The steadiest desk in the ranking: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.
Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.